The Redwood City, Calif.-based company posted losses of $9.7 million, or 32¢ per share, on sales of $107.9 million for the three months ended December 31, seeing losses grow 97.1% while sales grew 10.2% compared with the same period during the previous year.
Losses per share for the quarter were just behind the 21¢ consensus on Wall Street, where analysts expected to see sales of $107.1 million, which the company topped.
For the full year, Nevro reported losses of approximately $49 million, or $1.64 per share, on sales of approximately $387.3 million, seeing losses grow 31.8% while sales grew 18.6% compared with the same period during the previous year.
Losses per share for the year were also behind the Wall Street consensus, at $1.53, but sales topped analysts expectations of $386.3 million.
Nevro also released guidance for 2019, saying it expects to post sales of $400 to $410 million, according to a press release.
At DeviceTalks Boston, Tyler Shultz will give attendees an inside look at Theranos and how he was able to sound the alarm after he realized the company was falling apart. Shultz will take attendees behind the story that everyone is talking about: the rise and fall of Elizabeth Holmes and her diagnostic company, Theranos.
Join Shultz and 1,000+ medical device professionals at the 8th annual DeviceTalks Boston.